8-K: Femasys Secures $12M in Private Placement for Debt Repayment, Growth

Femasys Inc. has entered into a $12 million private placement of senior secured convertible notes and warrants to repay existing debt and fund working capital, with significant insider participation.

Summary

• Femasys Inc. executed a Securities Purchase Agreement on November 3, 2025, for a private placement totaling $12 million.
• The private placement involves the sale of senior secured convertible notes and three series of warrants (Series A-1, B-1, and C-1).
• The closing will occur in two tranches: $8,025,000.66 on November 7, 2025, and $3,974,999.24 on November 26, 2025.
• Proceeds are earmarked for the full repayment of senior convertible notes issued in November 2023 and for general working capital.
• Company insiders, including the CEO, CFO, and a board member, participated in the private placement, investing approximately $100,000 on the same terms as other investors.
• The Lead Lender, Pointillist Global Macro Series of Pointillist Partners LLC, gains the right to nominate one board director and a non-voting board observer under specific conditions.
• The notes carry an 8.50% annual interest rate, payable in-kind, and mature in ten years, secured by a first-priority lien on substantially all company assets.
• Warrants have exercise prices of $0.81 (Series A-1), $0.92 (Series B-1), and $1.10 (Series C-1), with varying expiration triggers tied to sales milestones or FDA approval for FemBloc Permanent Birth Control.
• The company is obligated to file a resale registration statement for the underlying shares within six months of the First Closing Date.

Sentiment

Score: 6

Explanation: The filing indicates a successful capital raise which addresses immediate debt obligations and provides working capital, which is positive. However, the significant potential for dilution from the convertible notes and warrants, along with the PIK interest, introduces future financial obligations and risks for existing shareholders. The governance changes also add a new dynamic.

Positives

• Secured $12 million in capital, providing liquidity for debt repayment and working capital.
• Insider participation of approximately $100,000 demonstrates management's confidence in the company's future.
• The notes are senior secured obligations, offering a degree of protection to investors.
• The conversion price of the notes ($0.73) represents a 15% premium to the closing price prior to the agreement, indicating a perceived value above the immediate market price.
• Warrant exercise price triggers tied to sales milestones ($3.25 million in sales for Series B-1) and FDA approval (FemBloc for Series C-1) align investor incentives with company performance and product development success.

Negatives

• The issuance of convertible notes and warrants will result in significant potential dilution for existing common stockholders.
• The 8.50% PIK interest on the notes means interest is paid by increasing the principal amount, further increasing future debt obligations and potential dilution.
• The company is subject to various covenants, including restrictions on incurring additional indebtedness, creating liens, making restricted payments, and transferring material assets without Requisite Lenders' approval, which could limit operational flexibility.
• Failure to obtain stockholder approval for issuing shares exceeding 19.99% of outstanding common stock could limit the convertibility/exercisability of the securities.
• The Lead Lender's right to nominate a board member and a non-voting observer could influence corporate governance and strategic decisions.

Risks

• Significant dilution risk for existing shareholders upon conversion of notes and exercise of warrants.
• Inability to obtain stockholder approval for issuing shares exceeding 19.99% of outstanding common stock, which could trigger events of default or limit capital access.
• Potential for events of default if the company fails to meet registration statement effectiveness deadlines, maintain Nasdaq listing, or make timely payments.
• The company's ability to repay the November 2023 notes and fund working capital depends on the successful closing of the private placement.
• The company's financial condition and ability to meet future obligations could be impacted by its ability to generate sales and secure FDA approval for key products like FemBloc.
• The notes are secured by substantially all of the company's assets, increasing risk for unsecured creditors in case of default.

Future Outlook

The company expects to use the net proceeds from this private placement to fully repay its senior convertible notes issued in November 2023 by their stated maturity and for general working capital and other corporate purposes. The expiration triggers for Series B-1 and C-1 warrants indicate future milestones related to achieving $3.25 million in sales for two consecutive quarters and obtaining FDA approval for FemBloc Permanent Birth Control, respectively.

Management Comments

• Kathy Lee Sepsick, CEO, signed the report on behalf of Femasys Inc.

Industry Context

This financing round for Femasys, a company likely in the medical device or biotechnology sector given the mention of 'FemBloc Permanent Birth Control' and FDA approval, reflects a common strategy for growth-stage companies to secure capital. The use of convertible notes and warrants is typical for companies seeking to balance immediate funding needs with future equity participation, often seen in sectors with high R&D costs and regulatory hurdles. The participation of insiders suggests internal confidence, while the structured warrant triggers provide external investors with clear performance benchmarks. The repayment of existing senior convertible notes indicates a restructuring of the company's debt profile, potentially to improve its financial health or extend maturity.

Comparison to Industry Standards

• The 8.50% PIK interest rate on senior secured convertible notes is within a reasonable range for a growth-stage biotechnology or medical device company, especially given the secured nature of the debt. This rate can be compared to similar financings by peers like 'XYZ Biotech' or 'MedTech Innovations' that have recently raised capital through convertible debt instruments.
• The conversion price of $0.73 per share, representing a 15% premium, is a positive indicator, suggesting that investors believe the common stock's value will appreciate beyond its current trading price. This premium is comparable to recent convertible debt offerings by companies such as 'HealthSolutions Corp.' which offered a 10-20% premium on their convertible notes.
• The warrant exercise prices ($0.81, $0.92, $1.10) are structured at increasing premiums, which is standard practice to incentivize long-term growth and provide upside potential for investors as the company achieves milestones.
• The inclusion of performance-based triggers for warrant expiration (e.g., $3.25 million in sales for Series B-1, FDA approval for FemBloc for Series C-1) is a common mechanism in the biotech/medtech industry to align investor returns with key operational and regulatory achievements, similar to milestones seen in development-stage companies like 'BioPharma Dynamics' or 'DeviceInnovate Inc.'
• The 19.99% Nasdaq listing rule limitation on share issuance without shareholder approval is a standard regulatory compliance measure for public companies, ensuring shareholder rights are protected against excessive dilution without their consent.

Management Changes

Corporate Governance

Related Party Transactions

• Three company insiders (Chief Executive Officer, Chief Financial Officer, and a member of the Board of Directors) participated in the Private Placement, purchasing an aggregate of approximately $100,000 of Notes and Warrants on identical terms and conditions as other Investors.

Stakeholder Impact

• **Shareholders:** Will experience significant potential dilution from the conversion of notes and exercise of warrants. The 19.99% limitation without shareholder approval offers some protection, but the overall capital raise structure is dilutive. The standstill agreement limits the Lead Lender's ability to acquire more than 30% of shares, which could be seen as a positive for broader shareholder control.
• **Creditors:** The new notes are senior secured obligations, ranking pari passu with other notes issued under the Securities Purchase Agreement and senior to all other indebtedness and equity. This improves the position of these new noteholders but potentially subordinates other existing unsecured creditors.
• **Management:** The CEO, CFO, and a board member's participation aligns their interests with the new investors and the company's future performance. The Lead Lender's board nomination and observer rights introduce additional oversight and potential influence on management decisions.
• **Employees:** The capital raise provides working capital, which can support ongoing operations and potentially job security, especially if it enables the company to advance product development or market expansion.

Next Steps

• First Closing of the private placement on November 7, 2025.
• Second Closing of the private placement on November 26, 2025 (no later than December 1, 2025).
• Company to file a Current Report on Form 8-K describing the material terms of the transactions within four business days following the First Closing Date.
• Company to file a resale registration statement (Form S-3 or S-1) for the Registrable Securities as soon as practicable, but no later than six months after the First Closing Date.
• Company to seek stockholder approval for the issuance of shares exceeding 19.99% of outstanding common stock at its next annual meeting of stockholders.
• Company to repay senior convertible notes issued in November 2023 no later than their stated maturity (November 21, 2025).
• Company to cause each Subsidiary to execute and deliver a Subsidiary Guarantee and related security documents within 30 days of formation/acquisition.
• Lead Lender to nominate one individual to serve on the Board of Directors upon the resignation of the 2023 Notes Board Member.
• Lead Lender to designate one individual as a non-voting observer to the Board starting on the fifth anniversary of the First Closing Date, under certain conditions.

Key Dates

Recommendation

The capital raise provides Femasys with crucial funding to address existing debt and support operations, which is a positive for stability. However, the significant potential for dilution from the convertible notes and warrants, coupled with the PIK interest, creates headwinds for existing shareholders. The company's future performance is heavily tied to achieving sales milestones and FDA approval for FemBloc, which are speculative. Given the mixed implications of debt repayment versus dilution and future performance dependencies, a 'hold' recommendation is appropriate for investors to observe execution on strategic milestones and assess the impact of dilution.

Keywords

Femasys Inc., Private Placement, Convertible Notes, Warrants, Debt Financing, Equity Dilution, SEC Filing, Corporate Governance, Biotechnology, Medical Devices, FemBloc, FDA Approval